Labbé, RP;
Vessillier, S;
Rafiq, QA;
(2021)
Lentiviral vectors for t cell engineering: Clinical applications, bioprocessing and future perspectives.
Viruses
, 13
(8)
, Article 1519. 10.3390/v13081519.
Preview |
Text
Rafiq_Lentiviral vectors for t cell engineering- Clinical applications, bioprocessing and future perspectives_VoR.pdf - Published Version Download (3MB) | Preview |
Abstract
Lentiviral vectors have played a critical role in the emergence of gene-modified cell ther-apies, specifically T cell therapies. Tisagenlecleucel (Kymriah), axicabtagene ciloleucel (Yescarta) and most recently brexucabtagene autoleucel (Tecartus) are examples of T cell therapies which are now commercially available for distribution after successfully obtaining EMA and FDA approval for the treatment of blood cancers. All three therapies rely on retroviral vectors to transduce the therapeutic chimeric antigen receptor (CAR) into T lymphocytes. Although these innovations rep-resent promising new therapeutic avenues, major obstacles remain in making them readily available tools for medical care. This article reviews the biological principles as well as the bioprocessing of lentiviral (LV) vectors and adoptive T cell therapy. Clinical and engineering successes, shortcomings and future opportunities are also discussed. The development of Good Manufacturing Practice (GMP)-compliant instruments, technologies and protocols will play an essential role in the development of LV-engineered T cell therapies.
| Type: | Article |
|---|---|
| Title: | Lentiviral vectors for t cell engineering: Clinical applications, bioprocessing and future perspectives |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.3390/v13081519 |
| Publisher version: | https://doi.org/10.3390/v13081519 |
| Language: | English |
| Additional information: | This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited |
| Keywords: | cytomegalovirus; transplant; outcomes; functional status |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > UCL BEAMS UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Engineering Science UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Engineering Science > Dept of Biochemical Engineering |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10133678 |
Archive Staff Only
 |
View Item |
